Comparing Capstone Therapeutics (CAPS) & The Competition

Capstone Therapeutics (NASDAQ:CAPS) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its peers? We will compare Capstone Therapeutics to similar companies based on the strength of its dividends, analyst recommendations, institutional ownership, earnings, valuation, profitability and risk.

Profitability

This table compares Capstone Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-12.40%	-29.50%	-10.60%
Capstone Therapeutics Competitors	-906.16%	-572.54%	-29.84%

Volatility & Risk

Capstone Therapeutics has a beta of -0.96, indicating that its stock price is 196% less volatile than the S&P 500. Comparatively, Capstone Therapeutics’ peers have a beta of 0.90, indicating that their average stock price is 10% less volatile than the S&P 500.

Earnings & Valuation

This table compares Capstone Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Capstone Therapeutics	$44.88 million	-$2.56 million	-0.84
Capstone Therapeutics Competitors	$918.26 million	-$40.68 million	10.00

Capstone Therapeutics’ peers have higher revenue, but lower earnings than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations and price targets for Capstone Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1	0	0	0	1.00
Capstone Therapeutics Competitors	6288	12372	38042	1199	2.59

As a group, “MED – BIOMED/GENE” companies have a potential upside of 54.56%. Given Capstone Therapeutics’ peers stronger consensus rating and higher possible upside, analysts clearly believe Capstone Therapeutics has less favorable growth aspects than its peers.

Institutional & Insider Ownership

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 51.3% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 59.1% of Capstone Therapeutics shares are held by company insiders. Comparatively, 13.4% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Capstone Therapeutics peers beat Capstone Therapeutics on 8 of the 13 factors compared.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.